Kanilad

Lacosamide, the active ingredient in Kanilad, is a sodium channel blocker presented as an oral formulation for oral use. It treats partial‑onset seizures and primary generalized tonic‑clonic seizures in patients requiring antiepileptic therapy.

GNH USA supplies Kanilad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic drug that modulates neuronal excitability in seizure disorders.

Partial‑onset seizures: reduces seizure frequency and improves seizure control. Primary generalized tonic‑clonic seizures: helps achieve seizure freedom and lowers seizure recurrence. Adjunct therapy for epilepsy: used alongside other antiepileptics to enhance overall seizure management.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Fatigue: increased tiredness or lack of energy. - Vision changes: blurred or double vision. - Tremor: involuntary shaking of limbs.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, especially PR‑interval prolongation. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation. - Liver enzyme elevation: significant increase in hepatic transaminases. - Hypersensitivity: anaphylaxis or severe allergic response. - Respiratory depression: marked reduction in breathing effort.

Before initiating therapy, clinicians should evaluate patient history and monitor for specific risks.

Pregnancy: Category C – weigh potential benefits against fetal risks. Renal impairment: dose adjustment may be required. Cardiac disease: monitor ECG for PR‑interval changes. Concomitant CNS depressants: assess for additive sedation. Alcohol use: advise moderation to avoid enhanced dizziness. Store at ambient temperature: keep below 25°C, retain original packaging, and protect from moisture.

Lacosamide can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid): - CYP2C19 inhibitors: may increase lacosamide plasma levels. - Strong CYP3A4 inducers: may reduce therapeutic effect. - Other sodium channel blockers: risk of additive cardiac conduction delays.

Moderate Interactions (Monitor Closely): - Anticoagulants: potential alteration of INR values. - Opioids: enhanced central nervous system depression. - Alcohol: increased dizziness and sedation.